DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral)
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to examine whether patients who have acute or early chronic
hepatitis C virus (HCV) infection can be treated effectively and safely with an
interferon-sparing regimen that combines a new direct acting antiviral drug (sofosbuvir) with
one of the standard treatments for chronic hepatitis C (ribavirin). In particular, this study
will investigate whether treatment of acute or early chronic HCV can be shortened. The study
will assess efficacy by looking at the proportion of people who clear the virus (have no
virus detectable in their blood) at the end of treatment, and 1, 3 and 6 months after
treatment.
The hypothesis is that short course (6 weeks) dual therapy using sofosbuvir and RBV will
result in successful virological eradication in the majority (≥80%) of subjects treated for
recently acquired HCV.